Luminex Corporation (LMNX) : Investment Management Of Virginia reduced its stake in Luminex Corporation by 0.22% during the most recent quarter end. The investment management company now holds a total of 952,334 shares of Luminex Corporation which is valued at $20,618,031 after selling 2,102 shares in Luminex Corporation , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Luminex Corporation makes up approximately 4.99% of Investment Management Of Virginia’s portfolio.
Other Hedge Funds, Including , Renaissance Technologies reduced its stake in LMNX by selling 4,940 shares or 0.49% in the most recent quarter. The Hedge Fund company now holds 1,002,900 shares of LMNX which is valued at $21,712,785. Luminex Corporation makes up approx 0.04% of Renaissance Technologies’s portfolio.Rhumbline Advisers reduced its stake in LMNX by selling 15,870 shares or 20.61% in the most recent quarter. The Hedge Fund company now holds 61,137 shares of LMNX which is valued at $1,323,616.Blackrock Advisors reduced its stake in LMNX by selling 114 shares or 0.59% in the most recent quarter. The Hedge Fund company now holds 19,169 shares of LMNX which is valued at $415,009.Dekabank Deutsche Girozentrale boosted its stake in LMNX in the latest quarter, The investment management firm added 4,500 additional shares and now holds a total of 23,000 shares of Luminex Corporation which is valued at $507,150. Luminex Corporation makes up approx 0.01% of Dekabank Deutsche Girozentrale’s portfolio.Wall Street Access Asset Management boosted its stake in LMNX in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 244,519 shares of Luminex Corporation which is valued at $5,240,042. Luminex Corporation makes up approx 3.07% of Wall Street Access Asset Management’s portfolio.
Luminex Corporation closed down -0.12 points or -0.57% at $21.08 with 1,31,112 shares getting traded on Monday. Post opening the session at $21.25, the shares hit an intraday low of $21.04 and an intraday high of $21.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Luminex Corporation reported $0.33 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.18. The company had revenue of $64.17 million for the quarter, compared to analysts expectations of $61.00 million. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Many Wall Street Analysts have commented on Luminex Corporation. Luminex Corporation was Upgraded by JP Morgan to ” Neutral” on Aug 18, 2016.
Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Companys xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Companys xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Companys products include Instruments Consumables Software and Assay Product Families.